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Introduction
Rheumatoid arthritis (RA) is a major immune-mediated
human disease of unknown cause. Nevertheless, cumula-
tive evidence suggests that cytokines are important medi-
ators in its pathology [1]. These substances, especially the
so-called proinflammatory cytokines, such as IL-1, tumor
necrosis factor-α, and IL-6, play a pivotal role in the pathol-
ogy of RA. Recently, Ohshima et al. showed that IL-6 is
essential for the development of antigen-induced arthritis,
an experimental autoimmune arthritis model that resem-
bles RA histologically [2]. Furthermore, results of a recent
clinical trial of anti-IL-6-receptor antibody therapy for RA
support this idea [3] (reviewed in [4]). However, the mole-
cular mechanisms by which IL-6 is involved in joint
destruction in RA have not yet been identified. A detailed
study of gp130∆STAT/∆STAT mice, in which gp130-mediated
signal transducer and activator of transcription (STAT)
signal was disrupted, showed that lack of STAT-mediated
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Abstract
IL-6 is a multifunctional cytokine produced by lymphoid and nonlymphoid cells; it regulates immune
responses, acute-phase reactions, and inflammation. IL-6 signaling is mediated exclusively by the
common signal-transducing component gp130, which is also essential for signal transduction of other
cytokines of the leukemia inhibitory factor (LIF)/IL-6 family. M Ernst and colleagues generated and
studied knock-in mice (gp130∆STAT/∆STAT), in which all STAT-binding sites (sites binding signal
transducers and activators of transcription) were deleted from their gene encoding gp130 but binding
sites for both Janus kinases (JAKs) and for the protein tyrosine phosphatase-2 (SHP-2) were
preserved. They found that this mutant mouse displayed a blastocyst implantation defect,
gastrointestinal ulceration, and, interestingly, severe joint disease with representative features of
rheumatoid arthritis. Synovial cells from this mouse exhibited mitogenic hyper-responsiveness to
cytokines of the LIF/IL-6 family, a phenomenon that was caused by sustained gp130-mediated SHP-
2/Ras/Erk activation due to a defect in the induction of SOCS-1 (suppressor of cytokine signaling-1;
also known as SSI or JAB). This suppressor, induced by STAT signaling, regulates cytokine signaling.
It is, therefore, conceivable that the disturbance of the balanced activation between the STAT and
SHP-2/Ras/Erk signal pathways causes the joint disease in the gp130∆STAT/∆STAT mouse. These
findings may be beneficial in the elucidation of the cause and the treatment of rheumatoid arthritis in
humans.
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induction of suppressor of cytokine signaling-1 (SOCS-1)
accelerates the SHP-2/Ras/Erk signal cascade that would
be downregulated by SOCS-1 induction; the acceleration
eventually resulted in severe joint disease [5].
gp130 signal cascades in IL-6
The IL-6 receptor consists of two molecules: one is an 80-
kDa IL-6-binding protein (α chain) and the other is a 130-
kDa signal transducer, gp130 (β chain), which is shared by
the receptors for other cytokines of the IL-6 family, includ-
ing IL-11, leukemia inhibitory factor (LIF), cardiotrophin-1,
oncostatin M, and ciliary neurotrophic factor. IL-6 signaling
is exclusively regulated by gp130, which contains two
motifs conserved among the cytokine receptor family,
known as Box1 and Box2 (Fig. 1). The membrane-proximal
region containing Box1 and Box2 is sufficient for Janus
kinase (JAK) to be activated through gp130. gp130 con-
tains six tyrosines in its cytoplasmic region. Tyr-757 is
essential for the tyrosine phosphorylation of SHP-2 and
subsequent activation of the Erk mitogen-activated protein
kinase (MAPK), while the group of Tyr-765/812/904/914
regulates the binding and activation of STAT1 and STAT3
(see Fig. 1). The STAT3-mediated signal emanating from
gp130 is essential and sufficient for the regulation of differ-
entiation and apoptosis of cells and to induce acute-phase
proteins [6]. A previous report on a series of knock-in
mouse lines, in which gp130-dependent STAT3 and/or
SHP-2 signal was disrupted, indicated that gp130-medi-
ated SHP-2 signals not only positively regulate Erk activa-
tion but also negatively regulate STAT3 activation [7] (see
Fig. 1). It is also known that STAT-mediated signals induce
the expression of proteins of the SOCS family, which
inhibit JAK-mediated substrate phosphorylation. Thus, the
duration and intensity of the signal transmission induced by
gp130 are also limited by resulting protein(s) of the SOCS
family [8–10] (see Fig. 1). These findings indicate that
STAT-mediated signals and SHP-2-mediated signals
cross-inhibit each other and presumably provide a balance
between these two signalings in vivo. To evaluate the phys-
iological roles of these two gp130-mediated signal cas-
cades, we need to establish mutant mice that can transmit
only one signal of these two.
Joint disease in the gp130∆ ∆STAT/∆ ∆STAT mouse
gp130∆STAT/∆STAT mice, under specific, pathogen-free con-
ditions, spontaneously exhibited swelling of one or more of
the large, weight-bearing joints and flexion deformities of
the bilateral hind legs [5]. These changes occurred young
and consistently progressed, albeit with various degrees
of severity. The histological examination of clinically
affected joints in young gp130∆STAT/∆STAT mice revealed
enlargement of the synovial space, synovial hyperplasia
and pannus formation, cartilaginous overgrowth in the
menisci, and destruction and deformation of the articular
surfaces. In addition, the knee joints of older mutant mice
showed destruction and erosion of the articular cartilage
as well as expansion of the synovial space. Later, inflam-
matory cells, mostly lymphocytes and macrophages, were
found in the synovium and subsynovial tissues of the dis-
eased joints. Taken together, these findings indicate that
the joint disease of these mutant mice illustrated destruc-
tion of articular cartilage with features of chronic synovitis
in various joints, including the major weight-bearing ones.
Molecular mechanism of joint disease in
gp130∆ ∆STAT/∆ ∆STAT mice
Cartilage destruction associated with synovial hyperplasia
is a major event in the early, effector phase of RA. Proin-
flammatory cytokines, including IL-6, are known to be
involved in cartilage destruction in the disease. IL-6 is a
potent mitogen for synovial fibroblasts in inflammatory joint
diseases, including RA [11]. Mutant synovial fibroblasts
derived from the clinically unaffected knee joints exhibited
high sensitivity and a proliferative response to IL-6 in com-
parison with those from control mice. This hyper-respon-
siveness of the mutant synovial cells to IL-6 is caused by
sustained activation of the SHP-2/Ras/Erk pathway. Tran-
scription of genes of the SOCS family, which are negative
regulatory molecules, is activated by STAT-mediated
signals. SOCS-1 in particular, which can be induced by
Figure 1
Diagrammatic representation of reciprocal functions of signal
cascades through the activation of gp130. The STAT-mediated signal
induces the SOCS-1 protein, which is a suppressor of JAKs; and
SOCS-1 inhibits both STAT and SHP-2/Ras/Erk mitogen-activated
protein kinase activation. On the other hand, the SHP-2-mediated
signal inhibits STAT3 activation. JAK = Janus kinase; SHP-2 = tyrosine
phosphatase-2; SOCS = suppressor of cytokine signaling; 
STAT = signal transducer and activator of transcription. Arthritis Research    Vol 4 No 3 Naka and Kishimoto
various cytokines, such as IFN-γ, IL-4, IL-2, and IL-6,
inhibits JAK-mediated cytokine signals by binding to JAKs
[8–10]. In the mutant synovial cells, SOCS-1 mRNA induc-
tion by IL-6 treatment was markedly less than that in control
cells. Moreover, synovial cells of IFN-γ-deficient SOCS-1–/–
mice, which are rescued from the perinatal lethality usually
associated with SOCS-1 deficiency [12], also displayed
sustained SHP-2/Ras/Erk activation by IL-6 stimulation in
comparison with control cells. In addition, the synovial cells
derived from these doubly mutant mice showed high
[3H]thymidine incorporation in response to IL-6. Collec-
tively, these findings show that the hyper-responsiveness of
gp130∆STAT/∆STAT synovial cells associated with the sus-
taining of SHP-2/Ras/Erk MAPK activation is due to a lack
of SOCS-1 induction, caused by failure of STAT-mediated
signals. That is, the disturbed balance between STAT and
SHP-2 pathways can be attributed to hyper-responsive-
ness of synovial cells to IL-6, resulting in joint disease.
Discussion
The study of gp130∆STAT/∆STAT mice reveals the following
two points. First, consistent with previous reports, gp130-
mediated STAT and SHP-2/Ras/Erk signal pathways play
reciprocal roles in immune responses, permitting balanced
activation of the two pathways [7,13]. The in vivo findings
have elucidated the direct involvement of sustained SHP-
2/Ras/Erk MAPK activation in joint disease. Second, IL-6
plays a key role in the development of RA [2]. The
gp130∆STAT/∆STAT mouse, which we can accept as a model
for spontaneously occurring RA, is a useful mouse model
for the study of the molecular mechanism of RA and should
provide new and important insights for an understanding of
the molecular mechanisms in the pathogenesis of RA.
However, no one yet knows whether endogenous IFN-γ-
mediated signals are involved in the joint disease of the
gp130∆STAT/∆STAT mouse. Hyper-responsiveness of synovial
cells from IFN-γ-deficient SOCS-1–/– mice was less
marked than in those from gp130∆STAT/∆STAT mice. Further-
more, previous studies showed that these doubly mutant
mice are free from any pathological changes [12,14].
These results suggest that IFN-γ may play a role in develop-
ment of RA in gp130∆STAT/∆STAT mice. It is worth mention-
ing that defective induction of SOCS-3 due to lack of
STAT3 may contribute to the joint disease of the
gp130∆STAT/∆STAT mouse: previous reports showed that
SOCS-3 can strongly inhibit IL-6 signaling by competing
for the SHP-2-gp130 interaction site by binding to the
SH2-domain-containing SHP-2-interaction site in gp130
[15,16]. IFN-γ-deficient gp130∆STAT/∆STAT mice and condi-
tional SOCS-3-deficient mice will give us these answers.
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